

Portfolio Problem at Zinca Inc.



Matthew Gurnani had just been hired as a business development analyst for a large pharmaceutical company, Zinca Inc. The first task that was entrusted on him was to prepare an analysis and a recommendation regarding what drug development projects the company should fund and carry on during the coming year. This was not a task to be taken lightly since most of the company's revenues came from the drugs that were successfully developed and launched on market. Also, the funding used this year for drug development was significant adding up to \$1 billion.

After discussing with Zinca's chief financial officer (CFO) George Pradalos, Matthew learned that whereas the primary goal was to maximize the overall return of the company, risk management was also getting increasingly more important. In particular, George felt that the company should forgo some return if that reduced risks significantly. However, Matthew was not sure whether that was possible and felt that a thorough analysis was needed. With this thought in mind, Matthew started his first assignment at Zinca.

To assist with the task, Matthew is given access to the company's drug development data. This data is summarized in two files. The first file is labelled as "drugs.csv" and it shows for each drug (i) the therapeutic area it belongs to, (ii) the time its completion takes, (iii) revenue in \$M to be obtained if the drug's development is completed, and (iv) the development cost in \$M for the coming year. The second file is labelled as "drugs_cov.csv" and it contains the covariance matrix for the drugs' revenues.

This case is intended to be used as a basis for class discussion, rather than to illustrate either effective or ineffective handling of an administrative situation. All names of individuals and companies are fictitious.

No part of this publication may be reproduced, stored in a retrieval system, used in a spreadsheet, or transmitted in any form or by any means — electronic, mechanical, photocopying, recording, or otherwise — without the permission of the George Washington University.

Matthew was aware of the optimal portfolio selection and allocation of funds in financial sector and he realized that the process was rather similar. However, the main difference was that it was not possible to fund a partial drug development project. In other words, a drug development project was either fully funded and selected into the portfolio or it was not funded at all and its development was postponed. An additional piece of information that George Pradalos was able to offer for Matthew, was that any unused funds (i.e., those not spent on drug development) could be invested risk free with a return of 3%.

Assignment

Make a report of about 3 pages (excluding figures, graphs and appendices) summarizing your results, your interpretation of the results and your conclusions and recommendations. You can include graphs and outputs in an appendix, but make sure to summarize and interpret the results in your report as well.

1. Framing the portfolio selection problem

Ignore risk management requirements for the time being. Suppose that the objective is to maximize the return of the drug portfolio. The constraints that the selected portfolio has to satisfy relate to *therapeutic area budget constraints* and *drug development pipeline constraints*. The therapeutic area budget constraints limit the maximum total drug development cost in the concerning therapeutic area. The budgets are as follows:

- \$100 million for oncology
- \$200 million for cardiovascular
- \$150 million for respiratory and dermatology
- \$100 million for transplantation
- \$300 million for rheumatology and hormone therapy
- \$100 million for central nervous system
- \$50 million for ophthalmics

The pipeline constraints are required to balance the drug development so that there is a steady state of drugs completed each coming future year. In particular, Zinca wants to enforce that at least (i) 15% of the funded drugs have 1 year time-to-market, (ii) 20% of the funded drugs have 2 or 3 years time-to-market, and (iii) 25% of the funded drugs have 4 or 5 years time-to-market.

- What is the mathematical formulation of the drug development portfolio selection problem?
- Copy the file “drug.ipynb” that can be found on blackboard. The python file contains a template for the model. Build the developed mathematical formulation using Python and Gurobi. **Save this model as “drug1.ipynb”**. Make a recommendation on which drugs to continue developing and which drugs to put on hold.
- What percent of the overall budget is used for drug development?

2. Incorporating risk management in the analysis

- How does the mathematical formulation for the drug development need to be appended to incorporate a constraint on the portfolio's variance? Update the model **"drug1.ipynb"** to include a constraint on the portfolio's variance. **Save this model as "drug2.ipynb"**.
- Illustrate an efficient frontier for the drug development portfolio problem. In the figure, show the entire efficient frontier with return on y-axis and standard deviation of the return on the x-axis.
- Use the efficient frontier to make a recommendation on how much risk to take and what drugs will be developed under this scenario.
- If the portfolio risk were to be minimized, what drugs would be chosen for development?

Suppose that Zinca receives a donation of \$50 million with the condition that this money has to be allocated to advance drug development in one of the therapeutic areas.

- Which therapeutic area you would recommend allocating the additional \$50 million if the goal is to maximize return? Hint: Update the model to have a binary variable associated with each therapeutic area, which is 1 if the additional funds are allocated on that therapeutic area.
- How does the allocation of the additional \$50 million depend on the willingness to take risk at Zinca? Interpret the results.

3. Company-wide budgeting

Once Matthew had completed his preliminary analysis, George Pradalos came to see him. He was wondering whether Zinca should change the way they budgeted the drug development. In particular, George asked if Matthew could look into the implications of having a company-wide budgeting rather than the current department-wide budgeting. In other words, the company-wide budget meant that the entire \$1000 million could be allocated across all drug development projects without specific constraints on different therapeutic areas. Ignore the availability of the additional \$50 million.

- How does the mathematical formulation change when the therapeutic area budget constraints are replaced by the company-wide budget?

- Develop the company-wide budget model. **Save this model as “drug3.ipynb”**. Consider first the risk neutral case (i.e., profit maximization). What changes does the company-wide budget imply (compared to the therapeutic area budgets) in terms of (i) selected projects, (ii) portfolio’s return, (iii) standard deviation of the portfolio’s return, and (iv) percent of funds allocated on projects? Explain these changes.
- How does the efficient frontier change if the company-wide budget is used?
- Would you recommend Zinca to use therapeutic area budgets or the company-wide budget? Explain your reasoning.

4. Managing extreme risks

Just when Matthew thought that he had completed the analysis, George dropped by. George said that he had heard from the grapevine that some of the competitors were selecting their drug development projects whilst accounting for the “extreme risk”. George clarified that by extreme risk he meant the portfolio’s return at the 5th percentile of its probability distribution. It is commonly referred as 95% Value at Risk (VAR) and can be interpreted as the portfolio’s return that occurs in the worst 5th percentile of the outcomes (or once in every 20th outcome). Thereby, George added, 95% VAR is considered to measure the extreme risk, see Figure 1.




Figure 1: 95% Value at Risk (VAR)

With this information and assuming that revenues from developed drugs are normally distributed, Matthew figured out that the portfolio's return at the 5th percentile can be constrained as follows

$$\sum_{i=1}^n z_i \mu_i - 1.645 \sigma_p \geq r,$$

where z_i are binary decision variables ($z_i=1$ if and only if a project i is selected), μ_i is the return of a drug i , σ_p is the standard deviation of the portfolio's return, and r is the minimum accepted return at 95% VAR for the portfolio. The constant -1.645 he obtained from the cumulative normal distribution table, which reflects that the worst 5% of the portfolio return is 1.645 times the standard deviation below the expected return. However, before he started to implement this formulation, he realized one problem in it. In particular, the formulation was not computationally tractable due to the standard deviation term σ_p resulting in square root of decision variables (and hence not being shown in a quadratic format). Therefore, Matthew spent further time to study how to reformulate this VAR constraint. He learned that the following second-order cone programming formulation made the optimization problem computationally amenable

$$\sum_{i=1}^n z_i \mu_i - 1.645 h \geq r, \quad (1)$$

$$h^2 \geq \sum_{i=1}^n \tau_i^2, \quad (2)$$

$$\boldsymbol{\tau} = \mathbf{L}^T \mathbf{z}, \quad (3)$$

$$h \geq 0, \quad (4)$$

where h is an auxiliary variable (i.e., helper decision variable), $\boldsymbol{\tau}$ is a $n \times 1$ vector of auxiliary variables (n being the total number of projects), and matrix \mathbf{L} is the lower triangular matrix obtained from the Cholesky factorization $\mathbf{L}\mathbf{L}^T = \mathbf{\Lambda}$ when $\mathbf{\Lambda}$ is the covariance matrix among the drugs.

- Replace the constraint on variance included in model “**drug2.ipynb**” by the VAR constraints (1) – (4). Ignore the availability of the additional \$50 million. **Save this model as “drug4.ipynb”**. Use the model “drug4.ipynb” to assess the maximum risk at the 95% VAR for the drug portfolio (if the portfolio is selected using a risk-neutral approach) and the minimum possible risk attainable at the 95% VAR for the drug portfolio? What are the expected returns of these portfolios? Compare these results to the 95% VAR and expected return obtained from model “drug1.ipynb”.
- Explain whether Zinca should be concerned about the extreme risk of its drug development portfolio?